Latest debt-to-equity ratio for Jupiter Neurosciences: -4.78 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-4.78
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
The latest debt-to-equity ratio for JUNS is -4.78. That is below the sector sector average of 0.2. Investors often review this figure alongside Jupiter Neurosciences's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, JUNS currently prints -4.78 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 2481.9% below the sector mean. Large gaps often invite a closer look at Jupiter Neurosciences's growth, margins, and balance sheet.
A debt-to-equity ratio of -4.78 for Jupiter Neurosciences is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with JUNS's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting JUNS's debt-to-equity ratio (-4.78), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.